Generex Biotechnology Corporation

generex.com

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care. In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

PRECISION NANOSYSTEMS IS NOW A PART OF DANAHER'S LIFE SCIENCES PLATFORM

Cytiva, Pall Corporation | June 02, 2021

news image

Danaher Corporation's Life Sciences platform has acquired precision NanoSystems (PNI). PNI is a global leader in technologies and solutions for developing genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher's Life Sciences platform and complement other businesses in the forum, including Cytiva and Pall. "PNI has advanced several exciting innovations, and we're thrilled to welcome this talented team," says Emmanuel Ligner, Danahe...

Read More

Medical, Industry Outlook

DESIGN THERAPEUTICS TO PRESENT PRECLINICAL DATA ON ITS GENETAC™ SMALL MOLECULE, DT-168, FOR THE TREATMENT OF FUCHS ENDOTHELIAL CORNEAL DYSTROPHY

Globenewswire | April 25, 2023

news image

Design Therapeutics, Inc. a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company’s novel GeneTAC™ small molecule, DT-168, an eye drop being developed for the treatment of Fuchs endothelial corneal dystrophy (FECD), will be presented during an oral session at the Association for Research in Vision and Ophthalmology 2023 Annual Meeting (ARVO 2023), which is being held in New Orl...

Read More

Cell and Gene Therapy

BIOINVENT AND TRANSGENE RECEIVE CTA APPROVAL FOR PHASE L/LLA STUDY OF NOVEL ONCOLYTIC VACCINIA VIRUS BT-001

BioInvent | December 22, 2020

news image

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech organization focused in on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech organization that designs and develops infection based for the therapy of cancer, reported they have received administrative endorsement in Belgium for a clinical trial application (CTA) for a Phase l/lla study of the novel oncolytic vacc...

Read More

Cell and Gene Therapy, Industrial Impact

VERTEX AND ENTRADA THERAPEUTICS ESTABLISH COLLABORATION TO DISCOVER AND DEVELOP ENDOSOMAL ESCAPE VEHICLE (EEV) THERAPEUTICS FOR MYOTONIC DYSTROPHY

Vertex | December 09, 2022

news image

Vertex Pharmaceuticals Incorporated and Entrada Therapeutics, Inc. announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle therapeutics for myotonic dystrophy type 1. The collaboration includes Entrada’s program for DM1, ENTR-701, which is in late-stage preclinical development. “Vertex’s strategy is to discover and develop transformative medicines for people with serious diseases, and DM1...

Read More
news image

Medical

PRECISION NANOSYSTEMS IS NOW A PART OF DANAHER'S LIFE SCIENCES PLATFORM

Cytiva, Pall Corporation | June 02, 2021

Danaher Corporation's Life Sciences platform has acquired precision NanoSystems (PNI). PNI is a global leader in technologies and solutions for developing genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher's Life Sciences platform and complement other businesses in the forum, including Cytiva and Pall. "PNI has advanced several exciting innovations, and we're thrilled to welcome this talented team," says Emmanuel Ligner, Danahe...

Read More
news image

Medical, Industry Outlook

DESIGN THERAPEUTICS TO PRESENT PRECLINICAL DATA ON ITS GENETAC™ SMALL MOLECULE, DT-168, FOR THE TREATMENT OF FUCHS ENDOTHELIAL CORNEAL DYSTROPHY

Globenewswire | April 25, 2023

Design Therapeutics, Inc. a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company’s novel GeneTAC™ small molecule, DT-168, an eye drop being developed for the treatment of Fuchs endothelial corneal dystrophy (FECD), will be presented during an oral session at the Association for Research in Vision and Ophthalmology 2023 Annual Meeting (ARVO 2023), which is being held in New Orl...

Read More
news image

Cell and Gene Therapy

BIOINVENT AND TRANSGENE RECEIVE CTA APPROVAL FOR PHASE L/LLA STUDY OF NOVEL ONCOLYTIC VACCINIA VIRUS BT-001

BioInvent | December 22, 2020

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech organization focused in on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech organization that designs and develops infection based for the therapy of cancer, reported they have received administrative endorsement in Belgium for a clinical trial application (CTA) for a Phase l/lla study of the novel oncolytic vacc...

Read More
news image

Cell and Gene Therapy, Industrial Impact

VERTEX AND ENTRADA THERAPEUTICS ESTABLISH COLLABORATION TO DISCOVER AND DEVELOP ENDOSOMAL ESCAPE VEHICLE (EEV) THERAPEUTICS FOR MYOTONIC DYSTROPHY

Vertex | December 09, 2022

Vertex Pharmaceuticals Incorporated and Entrada Therapeutics, Inc. announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle therapeutics for myotonic dystrophy type 1. The collaboration includes Entrada’s program for DM1, ENTR-701, which is in late-stage preclinical development. “Vertex’s strategy is to discover and develop transformative medicines for people with serious diseases, and DM1...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us